Results 121 to 130 of about 755,616 (163)

Neuron myelination is accelerated by Bruton’s tyrosine kinase inhibition via microglial extracellular vesicles

open access: yesFrontiers in Cellular Neuroscience
IntroductionThe altered myelin repair observed in demyelinating diseases such as multiple sclerosis (MS) potentially exposes axons to various stressors, with consequent neurodegeneration.
Matteo Tartaglia   +10 more
doaj   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 22, Page 6574-6606, November 2026.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown   +2 more
wiley   +1 more source

Thermodynamic characterisation of covalent ligand binding

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 22, Page 6704-6717, November 2026.
Background and Purpose Differential scanning fluorimetry (DSF) is a common and straightforward method to evaluate the thermal stability of proteins and has been heavily used for ligand binding characterisation as well as for screening. One class of compounds that is less typically evaluated by DSF are covalent binders.
Rebecca Hertzman   +4 more
wiley   +1 more source

Application of Mechanistic Modeling to Support Dose‐Relevant Decision Making for CAR‐T Cell Therapy in Oncology: A Systematic Scoping Review

open access: yesClinical and Translational Science, Volume 19, Issue 11, November 2026.
ABSTRACT CAR‐T therapy has improved outcomes in selected relapsed or refractory hematologic malignancies. However, rational dose‐relevant decision application remains challenging because the administered (nominal) cell dose does not reliably predict in vivo exposure, toxicity, or clinical response.
Dolapo Odujinrin, Graham McClelland
wiley   +1 more source

Early Integration of CAR T‐Cell Therapy in Mantle Cell Lymphoma: Expert Opinion in the Era of BTK Inhibitors

open access: yes
Hematological Oncology, Volume 44, Issue 6, November 2026.
Carlo Visco   +4 more
wiley   +1 more source

P1603: EFFICACY AND SAFETY OF BRUTON’S TYROSINE KINASE INHIBITOR ZANUBRUTINIB IN ITP

open access: yesHemaSphere, 2023
Qiu-Sha Huang   +9 more
doaj   +1 more source

Pirtobrutinib in Richter syndrome: Outcomes from the named patient programme in Italy

open access: yes
British Journal of Haematology, Volume 209, Issue 5, Page 2302-2306, November 2026.
Isacco Ferrarini   +19 more
wiley   +1 more source

Papers

open access: yes, 2008
work with signal transduction and gene expression profiling in B cells, characterising genes regulated by Bruton’s tyrosine ...
C. I. Edvard Smith   +3 more
core  

Healthy Participant Versus Patient Selection for Clinical Pharmacology Studies in Small‐Molecule Oncology Drug Development

open access: yes
Clinical and Translational Science, Volume 19, Issue 11, November 2026.
Paridhi Gupta   +3 more
wiley   +1 more source

Targeting Cell Signalling Pathways: A Short Review on Tyrosine Kinase Inhibitors

open access: yes
This short review discusses about tyrosine kinase inhibitors (TyKI) as a potential targeting cell signalling pathway blocker playing active role as anticancer drugs.
Tasleem, Nasreen Sultana, Sushma Desai
core   +1 more source

Home - About - Disclaimer - Privacy